Back to Search
Start Over
Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan
- Source :
- Oncology Research and Treatment
- Publication Year :
- 2021
- Publisher :
- S. Karger AG, 2021.
-
Abstract
- Treatment of cancer patients has become challenging when large parts of hospital services need to be shut down as a consequence of a local COVID-19 outbreak that requires rapid containment measures, in conjunction with the shifting of priorities to vital services. Reports providing conceptual frameworks and first experiences on how to maintain a clinical hematology/oncology service during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are scarce. Here, we report our first 8 weeks of experience after implementing a procedural plan at a hematology/oncology unit with its associated cancer center at a large academic teaching hospital in Germany. By strictly separating team workflows and implementing vigorous testing for SARS-CoV-2 infections for all patients and staff members irrespective of clinical symptoms, we were successful in maintaining a comprehensive hematology/oncology service to allow for the continuation of treatment for our patients. Notably, this was achieved without introducing or further transmitting SARS-CoV-2 infections within the unit and the entire center. Although challenging, our approach appears safe and feasible and may help others to set up or optimize their procedures for cancer treatment or for other exceedingly vulnerable patient cohorts.
- Subjects :
- Adult
Cancer Research
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Plan (drawing)
Medical Oncology
Unit (housing)
Tertiary Care Centers
Germany
Neoplasms
Pandemic
Humans
Medicine
Pandemics
Letter to the Editor
Procedural plan
Service (business)
SARS-CoV-2
business.industry
COVID-19
Hematology
medicine.disease
Oncology
Conceptual framework
Medical emergency
business
Hematology+Oncology
Subjects
Details
- ISSN :
- 22965262 and 22965270
- Volume :
- 44
- Database :
- OpenAIRE
- Journal :
- Oncology Research and Treatment
- Accession number :
- edsair.doi.dedup.....7d3a460b63b3abdeb719d63f4043484b
- Full Text :
- https://doi.org/10.1159/000515828